Commercial Development and Patient Benefit of Adoptive Cell Therapy (ACT) for Cancer

Impact: Technological impacts, Health and wellbeing, Economic, Policy


Immunotherapy is revolutionising cancer treatment. University of Manchester (UoM) researchers have been at the forefront of developing a branch of immune-oncology, Adoptive Cell Therapy (ACT), through molecular and pre-clinical research to delivery within the NHS as standard-of-care treatment. Development and commercialisation of ACT products has led to economic impact, with the UoM spin-out company Immetacyte expanding from 40 employees in 2019 to merger with Instil Bio in 2020 (raising USD172,000,000 in financing). Worldwide, thousands of patients have now benefited from these life-saving treatments and in the UK alone, around 200 patients per year currently receive commercial products.

Category of impact

  • Technological impacts
  • Health and wellbeing
  • Economic
  • Policy
1 Aug 2013 - 31 Jul 2020

Related information